Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia

International Journal of Infectious Diseases

Volumn 21, Issue 2, 2014, Pages 5-9

  Al Thaqafi, Abdul Hakeem O ^a,b   Farahat, Fayssal M ^a,b,c   Al Harbi, Maher I ^b   Al Amri, Abdul Fattah W ^a,b   Perfect, John R ^d  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c MENOUFIA UNIVERSITY   (Egypt)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Candidemia; Epidemiology; Saudi Arabia

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; MONOCROTALINE PYRROLE; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDA ZEYLANOIDES; CANDIDEMIA; CANDIDIASIS; CHILD; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SURVEILLANCE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PICHIA GUILLIERMONDII; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SAUDI ARABIA; SCHOOL CHILD; TERTIARY CARE CENTER; YOUNG ADULT; ANTIFUNGAL RESISTANCE; BLOOD CULTURE; CLINICAL ASSESSMENT; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA;

CANDIDEMIA; EPIDEMIOLOGY; SAUDI ARABIA;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; EPIDEMIOLOGICAL MONITORING; FEMALE; FLUCONAZOLE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SAUDI ARABIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84894343872     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.12.012     Document Type: Article

References (27)

1. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005, 7:429-439.
2. Almirante B., Rodriguez D., Park B. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43(4):1829-1835.
3. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in U.S. hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
4. Asmundsdottir L.R., Erlendsdottir H. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002, 40:3489-3492.
5. Bassetti M., Righi E., Costa A., Fasce R. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006, 6:21.
6. Blumberg H.M., Jarvis W.R., Soucie J.M., Edwards J.E., Patterson J.E., Pfaller M.A., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001, 33:177-186. National Epidemiology of Mycoses Survey (NEMIS) Study Group.
7. Zilberberg M.D., Shorr A.F., Kollef M.H. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008, 29:978-980.
8. Diekema D.J., Messer S.A., Brueggemann A.B., Coffman S.L. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002, 40:1298-1302.
9. Kibbler C.C., Seaton S., Barnes R.A., Gransden W.R., Holliman R.E., Johnson E.M., et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003, 54:18-24.
10. Pfaller M.A., Diekema D.J., Sheehan D.J. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006, 19:435-447.
11. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
12. Al-Tawfiq J. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004. Int J Infect Dis 2007, 11:239-244.
13. Al-Hedaithy S.A. The yeast species causing fungemia at a university hospital in Riyadh, Saudi Arabia, during a 10-year period. Mycoses 2003, 46:275-280.
14. Bukharie H.A. Nosocomial candidemia in a tertiary care hospital in Saudi Arabia. Mycopathologia 2001, 153:195-198.
15. Akbar D.H., Tahawi A.T. Candidemia at a university hospital: epidemiology, risk factors and predictors of mortality. Ann Saudi Med 2001, 21:178-182.
16. Osoba A.O., Al-Mowallad A.W., McAlear D.E., Hussein B.A. Candidemia and the susceptibility pattern of Candida isolates in blood. Saudi Med J 2003, 24:1060-1063.
17. Al-Jasser A.M., Elkhizzi N.A. Distribution of Candida species among bloodstream isolates. Saudi Med J 2004, 25:566-569.
18. Pfaller M.A., Diekema D.J., Rinaldi M.G., Barnes R., Hu B., Veselov A.V., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2007, 43:1735-1748.
19. Kao A.S., Brandt M.E., Pruitt W.R., Conn L.A., Perkins B.A., Stephens D.S., et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999, 29:1164-1170.
20. Cheng M.F., Yu K.W., Tang R.B., Fan Y.H., Yang Y.L., Hsieh K.S. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis 2004, 48:33-37.
21. Chow J.K., Golan Y., Ruthazer R., Karchmer A.W., Carmeli Y., Lichtenberg D., et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008, 46:1206-1213.
22. Morace G., Amato G., Bistoni F., Fadda G., Marone P., Montagna M.T., et al. Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol 2002, 40:2953-2958.
23. Holley A., Dulhunty J., Blot S., Lipman J., Lobo S., Dancer C., et al. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009, 33:554.
24. Rocco T.R., Reinsert S.E., Simms H.H. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 2000, 135:160-165.
25. Cuenca-Estrella M., Rodriguez D., Almirante B., Morgan J., Planes A.M., Almela M., et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005, 55:194-199.
26. Motta A.L., Almeida G.M., Almeida J.R., Burattini M.N., Rossi B.F. Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex. Braz J Infect Dis 2010, 14:441-448.
27. Kim S.H., Yoon Y.K., Kim M.J., Sohn J.W. Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections. Clin Microbiol Infect 2013, 19:62-68.